Assignee
LIPOSCIENCE INC
US·37 granted patents·11 pending applications·470 citations·filing 2000–2024
Top patents by PatentIndex Score
48 records- 0195US7790465B2Methods, systems and computer programs for assessing CHD risk using adjusted LDL particle number measurementsLIPOSCIENCE INC·Filed 2006·Granted Sep 7, 2010·29 cites·38 claims
- 0294US8013602B2NMR clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamplesLIPOSCIENCE INC·Filed 2005·Granted Sep 6, 2011·32 cites·50 claims
- 0394US6576471B2Methods, systems, and computer program products for analyzing and presenting NMR lipoprotein-based risk assessment resultsLIPOSCIENCE INC·Filed 2001·Granted Jun 10, 2003·92 cites·49 claims
- 0494US6518069B1Methods and computer program products for determining risk of developing type 2 diabetes and other insulin resistance related disordersLIPOSCIENCE INC·Filed 2000·Granted Feb 11, 2003·81 cites·45 claims
- 0593US6617167B2Method of determining presence and concentration of lipoprotein X in blood plasma and serumLIPOSCIENCE INC·Filed 2002·Granted Sep 9, 2003·61 cites·15 claims
- 0689US9928345B2Multiple-marker risk parameters predictive of conversion to diabetesLIPOSCIENCE INC·Filed 2015·Granted Mar 27, 2018·3 cites·23 claims
- 0788US11231429B2Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameterLIPOSCIENCE INC·Filed 2018·Granted Jan 25, 2022·2 cites·11 claims
- 0888US10613044B2NMR quantification of TMAOLIPOSCIENCE INC·Filed 2016·Granted Apr 7, 2020·2 cites·14 claims
- 0988US10504610B2Methods, systems and computer programs for assessing CHD risk using adjusted HDL article number measurementsLIPOSCIENCE INC·Filed 2016·Granted Dec 10, 2019·2 cites·20 claims
- 1088US10388414B2Multi-parameter diabetes risk evaluationsLIPOSCIENCE INC·Filed 2016·Granted Aug 20, 2019·6 cites·20 claims
- 1188US9541620B2NMR quantification of TMAOLIPOSCIENCE INC·Filed 2013·Granted Jan 10, 2017·5 cites·24 claims
- 1287US10365339B2NMR analyzers for clinical evaluation of biosamplesLIPOSCIENCE INC·Filed 2014·Granted Jul 30, 2019·5 cites·28 claims
- 1387US8386187B2Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating sameLIPOSCIENCE INC·Filed 2009·Granted Feb 26, 2013·14 cites·29 claims
- 1487US2024302389A1Cardiovascular Risk Evaluations Using a Risk Parameter That Includes an HDL and Inflammatory Biomarker Interaction ParameterLIPOSCIENCE INC·Filed 2024·Application pending·0 cites
- 1587US2024296902A1Methods, Systems and Computer Programs for Assessing CHD Risk Using Adjusted HDL Particle Number MeasurementsLIPOSCIENCE INC·Filed 2024·Application pending·0 cites
- 1686US9952232B2Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameterLIPOSCIENCE INC·Filed 2015·Granted Apr 24, 2018·4 cites·22 claims
- 1786US9792410B2Multi-parameter diabetes risk evaluationsLIPOSCIENCE INC·Filed 2013·Granted Oct 17, 2017·10 cites·25 claims
- 1886US7243030B2Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signalsLIPOSCIENCE INC·Filed 2003·Granted Jul 10, 2007·54 cites·45 claims
- 1986US2024125719A1NMR Quantification of TMAOLIPOSCIENCE INC·Filed 2023·Application pending·0 cites
- 2085US10386355B2CHD risk stratification evaluations for subjects with high levels of large HDL-PLIPOSCIENCE INC·Filed 2016·Granted Aug 20, 2019·3 cites·18 claims
- 2185US9361429B2Multi-parameter diabetes risk evaluationsLIPOSCIENCE INC·Filed 2013·Granted Jun 7, 2016·17 cites·52 claims
- 2282US11156685B2NMR analyzers for clinical evaluation of biosamplesLIPOSCIENCE INC·Filed 2019·Granted Oct 26, 2021·1 cites·16 claims
- 2381US9535144B2NMR quantification of TMAOLIPOSCIENCE INC·Filed 2013·Granted Jan 3, 2017·3 cites·22 claims
- 2481US9483612B2CHD risk stratification evaluations for subjects with high levels of large HDL-PLIPOSCIENCE INC·Filed 2013·Granted Nov 1, 2016·4 cites·40 claims
- 2581US2024096497A1Multi-Parameter Diabetes Risk EvaluationsLIPOSCIENCE INC·Filed 2023·Application pending·0 cites
- 2681US2025012820A1Multi-parameter metabolic vulnerability index evaluationsLIPOSCIENCE INC·Filed 2024·Application pending·0 cites
- 2781US2024304336A1Multiple-Marker Risk Parameters Predictive of Conversion to DiabetesLIPOSCIENCE INC·Filed 2024·Application pending·0 cites
- 2880US11988679B2Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameterLIPOSCIENCE INC·Filed 2022·Granted May 21, 2024·0 cites·30 claims
- 2980US11156621B2Multi-parameter metabolic vulnerability index evaluationsLIPOSCIENCE INC·Filed 2018·Granted Oct 26, 2021·2 cites·29 claims
- 3080US9470771B2NMR measurements of NMR biomarker GlycALIPOSCIENCE INC·Filed 2013·Granted Oct 18, 2016·10 cites·8 claims
- 3180US6653140B2Methods for providing personalized lipoprotein-based risk assessmentsLIPOSCIENCE INC·Filed 2002·Granted Nov 25, 2003·23 cites·23 claims
- 3278US11037683B2Multiple-marker risk parameters predictive of conversion to diabetesLIPOSCIENCE INC·Filed 2018·Granted Jun 15, 2021·1 cites·20 claims
- 3378US9483611B2Protective HDL particle number evaluationsLIPOSCIENCE INC·Filed 2013·Granted Nov 1, 2016·2 cites·18 claims
- 3477US10852293B2NMR measurements of NMR biomarker GlycALIPOSCIENCE INC·Filed 2016·Granted Dec 1, 2020·2 cites·12 claims
- 3576US11942187B2Methods, systems and computer programs for assessing CHD risk using adjusted HDL particle number measurementsLIPOSCIENCE INC·Filed 2019·Granted Mar 26, 2024·0 cites·11 claims
- 3675US11990243B2Multiple-marker risk parameters predictive of conversion to diabetesLIPOSCIENCE INC·Filed 2021·Granted May 21, 2024·0 cites·20 claims
- 3774US11703501B2CHD risk stratification evaluations for subjects with high levels of large HDL-PLIPOSCIENCE INC·Filed 2019·Granted Jul 18, 2023·0 cites·20 claims
- 3874US2022043086A1NMR Analyzers for Clinical Evaluation of BiosamplesLIPOSCIENCE INC·Filed 2021·Application pending·0 cites
- 3973US12130295B2NMR system and methods for multi-parameter metabolic vulnerability index evaluationsLIPOSCIENCE INC·Filed 2021·Granted Oct 29, 2024·0 cites·19 claims
- 4073US11782002B2NMR quantification of TMAOLIPOSCIENCE INC·Filed 2020·Granted Oct 10, 2023·0 cites·19 claims
- 4169US11692995B2NMR measurements of NMR biomarker GlycALIPOSCIENCE INC·Filed 2020·Granted Jul 4, 2023·0 cites·19 claims
- 4268US11710568B2Multi-parameter diabetes risk evaluationsLIPOSCIENCE INC·Filed 2019·Granted Jul 25, 2023·0 cites·26 claims
- 4367US2023024795A1Methods and Systems to Detect and Quantify the Amount of LP-X and Other Abnormal Lipoproteins in a Biosample Using NMR SpectroscopyLIPOSCIENCE INC·Filed 2022·Application pending·0 cites
- 4465US2024044826A1Metabolic vulnerability analyzed by nmrLIPOSCIENCE INC·Filed 2023·Application pending·0 cites
- 4561US11467171B2Methods and systems to detect and quantify the amount of LP-X and other abnormal lipoproteins in a biosample using NMR spectroscopyLIPOSCIENCE INC·Filed 2018·Granted Oct 11, 2022·0 cites·20 claims
- 4657US2017293007A1Quantitative NMR Clinical Analyzers With Automatic NMR Temperature Sensitivity Compensation that Accommodate Large Ambient Operational Temperature RangesLIPOSCIENCE INC·Filed 2017·Application pending·0 cites
- 4747US11124837B2Methods and systems for predicting colorectal cancer incidence and mortalityLIPOSCIENCE INC·Filed 2017·Granted Sep 21, 2021·0 cites·17 claims
- 4845US2022011388A1Methods to predict liver disease mortality using lipoprotein lp-zLIPOSCIENCE INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when LIPOSCIENCE INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →